{"disease":{"id":"von-hippel-lindau-syndrome","name":"von hippel lindau syndrome"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01496625","title":"National Eye Institute Biorepository for Retinal Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":650,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT06573723","title":"Institutional Registry of Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":380,"lead_sponsor_name":"Hospital Italiano de Buenos Aires","has_results":false},{"nct_id":"NCT01967537","title":"Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":341,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07275099","title":"Quality of Life, Psychological Impact, and Care-related Challenges in Patients Affected by Von Hippel-Lindau Syndrome.","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"IRCCS Ospedale San Raffaele","has_results":false},{"nct_id":"NCT03401788","title":"A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT07171905","title":"CAT-VHL Exploring the Role of Carbonic Anhydrase IX as Diagnostic and Theranostic Target in Von-Hippel Lindau Disease","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":38,"lead_sponsor_name":"IRCCS Ospedale San Raffaele","has_results":false},{"nct_id":"NCT01436227","title":"Pazopanib Hydrochloride in Treating Patients With Von Hippel-Lindau Syndrome","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT00089765","title":"Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":5,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":false},{"nct_id":"NCT03001349","title":"68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors","phase":"EARLY_PHASE1","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT03108066","title":"MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":4,"lead_sponsor_name":"Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":true},{"nct_id":"NCT02859441","title":"A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"National Eye Institute (NEI)","has_results":true}],"total":11},"guidelines":[],"source":"Drug Landscape verified database"}